The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma
Diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) accounting for approximately 30% of new lymphoma diagnoses in adult patients. Complete remissions (CRs) can be achieved in 45% to 55% of patients and cure in approximately 30–35% with anthracycline-containing combination chemotherapy. The ageadjust...
Main Authors: | Marco Gunnellini, Rita Emili, Stefano Coaccioli, Anna Marina Liberati |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2012/195484 |
Similar Items
-
High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma
by: Popp, Henning, et al.
Published: (2007-06-01) -
Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation
by: Arboe B, et al.
Published: (2017-06-01) -
Role of high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma
by: O A Gavrilina, et al.
Published: (2013-07-01) -
The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy
by: Lazaros J. Lekakis, et al.
Published: (2019-12-01) -
Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure
by: Jennifer J. Gile, et al.
Published: (2021-03-01)